OBJECTIVES: The current systematic review aims to synthesize existing feasibility studies on LRI among persons with cancer.
METHODS: A literature search was conducted from the databases PubMed, ScienceDirect, PsychArticles, Scopus, Psychology and Behavioral Science Collection, Cochrane, EBSCO, and other methods. Eligible articles were selected based on the predetermined inclusion criteria and data extraction revolved around the study design, intervention procedure, and feasibility and psychological outcome measures.
RESULTS: The search yielded 8,627 articles, to which respondents simultaneously receiving other forms of psychological interventions were excluded. Eight were selected for evaluation. Four were integrated interventions while the remaining were conducted with the standard intervention. The sample size range from 5 to 90 persons with cancer. All reviewed articles reported optimum feasibility, as presented by recruitment capability, participant retention rate, acceptability and satisfaction, intervention implementation, and evaluation of intervention outcome measures. However, a majority of psychological outcome measures indicated no statistical significance.
CONCLUSION: LRI is feasible to be implemented among persons with cancer, given the high acceptability and availability of resources for its implementation. The present review highlighted the preliminary knowledge on the feasibility of the intervention.
Materials and Methods: We conducted a prospective, cohort, observational study among patients with epilepsy who received VPA treatment at Hospital Kuala Lumpur. The patients were considered to have good control if they had a 50% or higher seizure reduction in the one-year study period compared with the previous year. The VPA reference range was generated from those patients who had good control and whose drug concentration values were available. Multiple logistic regression analysis with a backward likelihood ratio method was applied to assess the predicting factors for good seizure control.
Results: A total of 242 patients were recruited and followed up for one year. The VPA reference range was determined to be 40-85 mg/L. After multivariate analysis, significant predictive variables for good control were monotherapy [adjusted OR 4.74, 95% CI: 2.258, 9.947, p<0.001], non-smoking [adjusted OR 3.23, 95% CI: 1.099, 9.473, p=0.033], normal brain imaging results [adjusted OR 5.83, 95% CI: 2.507, 13.552, p<0.001], and the absence of stress [adjusted OR 19.98, 95% CI: 9.255, 42.764, p<0.001].
Conclusion: Monotherapy, non-smoking, normal brain imaging results, and the absence of stress are predictive of good seizure control in patients on VPA. However, a serum concentration of VPA in the reference range failed to predict good seizure control.
METHODS: A prospective study was conducted of 166 patients with CRSwNP, with or without asthma. The following variables were collected at baseline and after at least six months of continuous dupilumab therapy; SNOT-22, olfactory symptoms frequency, and ACT score.
RESULTS: Asthma prevalence in patients with CRSwNP was high (59.63%), and being female with a history of frequent use of oral corticosteroid (OCS) courses and repeated unsuccessful nasal and para-nasal surgeries for polyposis increased the likelihood of having underlying asthma by 2, 1 and 4 times more, respectively. Additionally, being asthmatic required a longer duration of dupilumab treatment. However, both the health-related quality of life and olfactory symptoms improved equally in both groups.
CONCLUSION: Even with associated comorbid asthma in patients with CRSwNP, treatment with dupilumab could improve the quality of life, olfactory symptoms, and asthma symptom control.